(Q37663648)

21 August 2017

1 reference

title

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups (English)

1 reference

21 August 2017

1 reference

4

Eric Van Ganse

1 reference

21 August 2017

1

Catherine Sermet

1 reference

21 August 2017

Veronique Andrieu

2

1 reference

21 August 2017

Brian Godman

series ordinal

3

1 reference

21 August 2017

Alan Haycox

series ordinal

5

1 reference

21 August 2017

Jean-Pierre Reynier

series ordinal

6

1 reference

21 August 2017

publication date

1 January 2010

1 reference

Applied Health Economics and Health Policy

21 August 2017

published in

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

7-24

1 reference

Can France keep its patients happy?

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Cancer survival in five continents: a worldwide population-based study (CONCORD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Prevalence and treatment of diabetes in France: trends between 2000 and 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

The drug budget silo mentality: the French case

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Opposition grows in France to new charges for drugs and ambulance trips

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

The last decade of Italian pharmaceutical policy: instability or consolidation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

An update on the first decade of the European centralized procedure: how many innovative drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

How can we regulate medicines better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Swedish registers to examine drug safety and clinical issues in RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Pharmacotherapeutic circles. Results of an 18-month peer-review prescribing-improvement programme for general practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

New medicines in primary care: a review of influences on general practitioner prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Incentives and pharmaceutical reimbursement reforms in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Public beliefs on antibiotics and respiratory tract infections: an internet-based questionnaire study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Reducing unnecessary prescriptions of antibiotics for acute cough: adaptation of a leaflet aimed at Turkish immigrants in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Determinants of self-medication with antibiotics in Europe: the impact of beliefs, country wealth and the healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Despite Financial Penalties, French Physicians' Knowledge of Regulatory Practice Guidelines Is Poor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

Prescribing Incentive Schemes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256162

21 January 2018

Identifiers

DOI

10.1007/BF03256162

1 reference

21 August 2017

1 reference